Fispemifene is a new, selective estrogen receptor antagonist that is being developed as an oral treatment for testosterone deficiency and associated disorders in men. Symptoms of low testosterone include sexual dysfunction, muscle wasting, reduced bone density, lowered energy levels and glucose intolerance. Unlike testosterone replacement therapies, fispemifene utilizes the body's normal feedback mechanism to increase testosterone levels into, but not beyond, the normal range. By blocking estrogen feedback to the pituitary with a drug like fispemifene, the pituitary increases LH and FSH secretion which increases testosterone secretion. As these rising testosterone levels feedback on the pituitary, LH and FSH secretion return toward normal and testosterone reaches a new, albeit higher, steady state level. Based on this mechanism of action, fispemifene is being studied for the treatment of androgen deficiency and associated symptoms. We believe that increased production of testosterone may treat many of the symptoms of low testosterone. In a Phase II study we conducted in hypogonadal men, fispemifene increased total testosterone levels by 78% over 28 days of treatment.
QuatRx : Fispemifene
Clinical Trial: Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors.
This could mean for me no more shots or high E2 problems.
Phil
QuatRx : Fispemifene
Clinical Trial: Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors.
This could mean for me no more shots or high E2 problems.
Phil